Fevipiprant

Fevipiprant

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Investigational
Pharmacokinetic data
Bioavailability	Unaffected by food
Metabolism	Hepatic glucuronidation
Elimination half-life	~20 hours
Excretion	Renal (≤30%)
Identifiers
IUPAC name {2-methyl-1-[4-(methylsulfonyl)-2-(trifluoromethyl)benzyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}acetic acid
CAS Number	872365-14-5
PubChem CID	23582412
ChemSpider	23582412
UNII	2PEX5N7DQ4
KEGG	D10631
ECHA InfoCard	100.243.911
Chemical and physical data
Formula	C19H17F3N2O4S
Molar mass	426.41 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O
InChI InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26) Key:GFPPXZDRVCSVNR-UHFFFAOYSA-N

Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D₂ receptor 2 (DP₂ or CRTh2).

As of 2016, it is in phase IIIclinical trials for the treatment of asthma.

On Monday, December 16, 2019, Switzerland-based Novartis officially announced that it was jettisoning fevipiprant from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. The firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.

See also

• Prostaglandin DP2 receptor
• Setipiprant